Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,169

Supreme Court revives FTC reverse payment challenge; says agreements can violate antitrust laws

Williams Mullen
-
USA
-
June 18 2013

The U.S. Supreme Court has issued one of its more anticipated rulings of this term in a decision that aims squarely at the intersection of antitrust

DNA and genetics patents: what impact will the Myriad decision have?

Dentons
-
USA
-
June 18 2013

Continuing a trend of narrowing the scope of patentable subject matter, the US Supreme Court's recentMyriad decision held that naturally occurring

Supreme Court says ‘reverse payment’ generic drug settlements are subject to rule of reason antitrust review

Debevoise & Plimpton LLP
-
USA
-
June 18 2013

On June 17, 2013, the U.S. Supreme Court issued a much anticipated ruling in Federal Trade Commission v. Actavis, Inc. regarding the validity of

Supreme Court rules that “pay for delay” generic drug patent settlements are not shielded from antitrust liability

Baker & Hostetler LLP
-
USA
-
June 18 2013

The Supreme Court has held that the antitrust laws may forbid patent settlements that delay the market entry of generic drugs in return for large

Not a biotech company? What Myriad might mean for you

Haynes and Boone LLP
-
USA
-
June 18 2013

You've seen all the articles about the Supreme Court's decision in Assoc. For Molecular Pathology v. Myriad Genetics Inc. and the end of DNA patents

US Supreme Court holds cDNA patent eligible, but isolated DNA not

Farella Braun & Martel LLP
-
USA
-
June 17 2013

On June 13, the United States Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. ___ (2013

What does the future hold in view of the Supreme Court decision on isolated genes and cDNA?

White & Case LLP
-
USA
-
June 17 2013

In a long-anticipated ruling, the US Supreme Court acknowledged Myriad Genetics' contribution in discovering the location and sequence of the BRCA1

Update on a recent Supreme Court antitrustintellectual property case: “reverse payment” settlement agreements under FTC v. Actavis, Inc. (June 17, 2013)

Lathrop & Gage LLP
-
USA
-
June 17 2013

Since the enactment of the Drug Price Competition and Patent Term Restoration Act of 1984 ("Hatch-Waxman Act"), "pay for delay" or "reverse payment"

Isolated DNA sequences are not patent-eligible, but cDNA still is

Husch Blackwell LLP
-
USA
-
June 17 2013

Are human genes patentable? On June 13, 2013, the U.S. Supreme Court held in Association for Molecular Pathology, et al. v. Myriad Genetics Inc. that

Supreme Court says isolated human genes cannot be patented

Quarles & Brady LLP
-
USA
-
June 17 2013

On June 13, 2013, the Supreme Court ruled unanimously that natural human genes, including isolated genes, cannot be patented, but cDNA that is

next >

Search results

Supreme Court revives FTC reverse payment challenge; says agreements can violate antitrust laws

DNA and genetics patents: what impact will the Myriad decision have?

Supreme Court says ‘reverse payment’ generic drug settlements are subject to rule of reason antitrust review

Supreme Court rules that “pay for delay” generic drug patent settlements are not shielded from antitrust liability

Not a biotech company? What Myriad might mean for you

US Supreme Court holds cDNA patent eligible, but isolated DNA not

What does the future hold in view of the Supreme Court decision on isolated genes and cDNA?

Update on a recent Supreme Court antitrustintellectual property case: “reverse payment” settlement agreements under FTC v. Actavis, Inc. (June 17, 2013)

Isolated DNA sequences are not patent-eligible, but cDNA still is

Supreme Court says isolated human genes cannot be patented

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea